Trovagene (TROV) Misses Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Trovagene (TROV) Misses Q4 EPS by 2c

Trovagene Reports Fourth Quarter and Year End 2016 Financial Results

March 15, 2017 4:04 PM EDT

SAN DIEGO, March 15, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company today reported financial results for the fourth quarter and year ended December 31, 2016.  Additionally, Trovagene announced a restructuring program that will support the Company's expansion into precision cancer therapeutics.

In a separate press release today, Trovagene announced a license agreement with Nerviano Medical Sciences that grants Trovagene exclusive global development and commercialization rights to PCM-075, an oral, investigative drug and a highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase... More